Makes protein-based drugs that normally require injections survive being swallowed, so patients can take them as pills.
At a glance
- Depends onMidstream position: 3 outgoing, 3 incoming connections
- Scale
Makes protein-based drugs that normally require injections survive being swallowed, so patients can take them as pills.
What this company is and how it runs — written from structure, not news.
Protagonist Therapeutics uses a chemical technique called constrained peptide cyclization — locking peptide bonds into rigid ring shapes — to make molecules that mimic injectable protein drugs survive stomach acid and digestive enzymes long enough to reach the bloodstream after being swallowed. That acid resistance is what makes rusfertide, an oral treatment for the blood disorder polycythemia vera, and icotrokinra, an oral treatment for plaque psoriasis, worth developing at all, because both therapeutic targets are already served by injectable biologics that physicians trust and use today. Both drugs are now in Phase 3 trials that must prove oral delivery works as well as those injectables — not just that it works, but that it matches them closely enough that doctors and regulators would accept a pill in place of a shot. If either trial falls short of that equivalence bar, the chemistry itself is not broken, but the entire commercial argument disappears, because an oral drug that is merely active but measurably weaker than the injectable standard it is trying to replace cannot displace that standard.
How does this company make money?
Once drugs are approved, the company sells rusfertide and icotrokinra through specialty pharmacies and collects revenue from those sales. For icotrokinra specifically, Johnson & Johnson pays milestone payments when the drug clears certain development hurdles, and will pay royalties on sales once it reaches the market. The company could also earn licensing fees from other drug companies that want to use its constrained peptide technology to develop their own new drugs.
What makes this company hard to replace?
Doctors prescribing rusfertide for polycythemia vera would need new clinical evidence and dosing guidance before they could confidently move a patient to a different oral hepcidin mimetic — none of which currently exists. Patients already enrolled in the ongoing Phase 3 trials cannot simply transfer to another treatment without violating the trial's rules and creating regulatory problems. The Johnson & Johnson licensing agreement contains exclusivity terms that prevent any other company from developing a competing oral IL-17 blocker using the same constrained peptide chemistry approach, meaning there is no direct alternative to icotrokinra built the same way.
What limits this company?
The company cannot move any faster than its two ongoing Phase 3 trials allow. No amount of money can shorten the time it takes to run those trials or produce the head-to-head data that regulators need before they will approve an oral drug to replace an injectable one. Until those results arrive, the entire platform is waiting at a single gate.
What does this company depend on?
The company cannot operate without its constrained peptide synthesis technology platform, which is the foundation of every drug it makes. It depends on specialized contract manufacturers that know how to perform peptide cyclization chemistry, because that process is not available at standard drug factories. The FDA's Investigational New Drug approvals for rusfertide and icotrokinra must remain in place for trials to continue. The Johnson & Johnson collaboration agreement funds icotrokinra's development, so losing that partnership would remove a critical source of both money and resources. Clinical research organizations running the Phase 3 trial sites across multiple countries are also essential to keeping both studies on track.
Who depends on this company?
Patients with polycythemia vera who currently need regular blood removal procedures would lose access to a potential daily pill if rusfertide development fails. Dermatology clinics treating plaque psoriasis would lose the only oral alternative in development to the injectable IL-17 drugs they currently use if icotrokinra trials fail. Johnson & Johnson would lose the lead drug in its oral immunology pipeline and would need to find a different way to pursue treatments targeting the IL-17 pathway.
How does this company scale?
Once the cyclization chemistry and design methods are established for one drug target, the same tools and protocols can be pointed at a new target without rebuilding everything from zero. That means adding new drug candidates does not require proportionally larger R&D teams or new laboratories. What does not get cheaper or faster, however, is clinical development: every new drug still needs its own multi-year trials and regulatory review before it can reach patients or generate revenue.
What external forces can significantly affect this company?
Medicare Part D drug price negotiations could push down what the company is allowed to charge for oral specialty drugs like rusfertide or icotrokinra if they reach the market, squeezing the revenue those drugs would generate. FDA changes to the rules around how closely an oral drug must match an injectable could force costly trial redesigns. European pharmaceutical rules restricting imports of peptide medicines made outside the EU could require the company to build or contract expensive manufacturing capacity inside Europe.
Where is this company structurally vulnerable?
If the FDA raised its requirements for oral drugs trying to replace injectables — for example, demanding that a pill be proven strictly better rather than just as good, or requiring additional data showing the drug behaves the same way in the body — both the rusfertide and icotrokinra trials would need to be redesigned from scratch. That would collapse the commercial case for the entire platform, because the whole premise rests on oral delivery being accepted as equivalent to injection.
Price is read as structure — trend, levels, range, peak and volatility drawn on the chart. It does not predict where price goes next.
Sign in to view price data.
Sign in1 interpretation currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsHow is this stock behaving?
Current close sits in the upper portion of the 14-week high-low range; current close sits in the upper portion of its 20-week Bollinger Bands; RSI sits above its 20-week recent mean (Bollinger %B applied to RSI).
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
The reported statements, read against the company's own industry.
1 interpretation currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company growing?
R&D expense is a large share of revenue; diluted share count has grown on a 6-year basis; stock-based compensation is a large share of trailing revenue.
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Companies that share the same coordination system — how they create, deliver, or capture value.
Companies that share active interpretations — structural patterns currently present in both stocks.
CompanyGraph